Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128667 | 0.87 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7409072 | 0.86 | ITGB3 (0.73) | ITGB3ITGA2B | |
| SCHEMBL7213400 | 0.86 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL5144246 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2B | |
| SCHEMBL7219511 | 0.85 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL7219528 | 0.85 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL7220986 | 0.80 | ITGB3 (0.83) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL24336949 | 0.80 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL344302 | 0.80 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL919675 | 0.79 | ITGB3 (0.95) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6623981-B2 | Detecting antibodies which bind integrin bound modulators; obtain sample, incubate with modulators and antibodies, form complexes, screen for bound complex | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20020132276-A1 | FACS method for detecton of GPIIb/IIIa inhibitor dependent activators in plasma samples | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-19 | — | — | US | claimed |
| US-20020081632-A1 | Assays to assess conformational changes of integrins induced by ligand binding based on electrophoretic mobility | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | claimed |
| US-20020081624-A1 | DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | claimed |
| US-6623981-B2 | Detecting antibodies which bind integrin bound modulators; obtain sample, incubate with modulators and antibodies, form complexes, screen for bound complex | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020132276-A1 | FACS method for detecton of GPIIb/IIIa inhibitor dependent activators in plasma samples | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-19 | — | — | US | disclosed |
| US-20020081632-A1 | Assays to assess conformational changes of integrins induced by ligand binding based on electrophoretic mobility | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-20020081624-A1 | DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |